WO2004087179A1 - A process for the preparation of ferutinine from ferula genus plants - Google Patents

A process for the preparation of ferutinine from ferula genus plants Download PDF

Info

Publication number
WO2004087179A1
WO2004087179A1 PCT/EP2004/003055 EP2004003055W WO2004087179A1 WO 2004087179 A1 WO2004087179 A1 WO 2004087179A1 EP 2004003055 W EP2004003055 W EP 2004003055W WO 2004087179 A1 WO2004087179 A1 WO 2004087179A1
Authority
WO
WIPO (PCT)
Prior art keywords
ferutinine
ferula
jaeschkenadiol
preparation
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/003055
Other languages
English (en)
French (fr)
Inventor
Ezio Bombardelli
Gabriele Fontana
Aldo Cristoni
Enrico Mercalli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indena SpA
Original Assignee
Indena SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SI200431757T priority Critical patent/SI1615651T1/sl
Priority to HK06107824.1A priority patent/HK1087618B/xx
Priority to AT04722572T priority patent/ATE517631T1/de
Priority to PL04722572T priority patent/PL1615651T3/pl
Priority to EP04722572A priority patent/EP1615651B1/en
Priority to JP2006504815A priority patent/JP4648305B2/ja
Priority to AU2004226853A priority patent/AU2004226853B2/en
Priority to BRPI0409166-3A priority patent/BRPI0409166B1/pt
Priority to CA2521100A priority patent/CA2521100C/en
Priority to KR1020057018336A priority patent/KR101132526B1/ko
Priority to KR1020117014703A priority patent/KR101169893B1/ko
Application filed by Indena SpA filed Critical Indena SpA
Priority to DK04722572.7T priority patent/DK1615651T3/da
Priority to US10/551,772 priority patent/US7371886B2/en
Publication of WO2004087179A1 publication Critical patent/WO2004087179A1/en
Priority to IL171230A priority patent/IL171230A/en
Priority to NO20054545A priority patent/NO333671B1/no
Anticipated expiration legal-status Critical
Priority to US12/058,776 priority patent/US20080248139A1/en
Priority to US12/816,671 priority patent/US8101215B2/en
Priority to US13/324,339 priority patent/US8247005B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/31—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/86—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with esterified hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/30—Azulenes; Hydrogenated azulenes

Definitions

  • the present invention relates to vegetable extracts from Ferula spp and to a process for isolating ferutinine from said extracts.
  • BACKGROUND OF THE INVENTION Numerous Ferula genus plants contain terpenes with estrogenic activity, known also as phytoestrogens, i.e. substances which regulate hormonal functions and are apparently a valid alternative to the use of synthetic hormones in the treatment of pre-menstrual syndrome and disorders related to menopause and aging. Extracts of some types of Ferula were used in ancient times as contraceptives and in the treatment of impotence and menopausal disorders. Recently, alcoholic extracts from Ferula asafoetida L. have been disclosed (WO 0230438) as anticancer drugs.
  • R is a straight or branched, saturated or unsaturated aliphatic acyl residue, or an optionally substituted aromatic acyl residue.
  • R groups are iso-valeroyl, angeloyl, benzoyl, -hydroxybenzyl, veratroyl or cinnammoyl.
  • Daucane esters from Ferula spp are estrogen modulators similar to SERMs (selective estrogen receptor modulators); among them, ferutinine (la) shows marked estrogenic activity, whereas the others have a rather mild activity.
  • ferutinine is an estrogen receptor alpha agonist (ER ⁇ ) and an estrogen receptor beta agonist/antagonist (ER ⁇ ). It has also been shown that ferutinine has higher binding to estrogen receptors than tamoxifen.
  • Object of the present invention is therefore a process for the preparation tinine (la)
  • “Daucane esters” means compounds of the general formula (I) as defined above; said esters can be obtained by extraction of the rhizomes or aerial parts of Ferula spp, preferably Ferula communis and Ferula hermonis, with conventional methods, for example by extraction with lower alcohols.
  • daucane esters can be obtained by extraction with supercritical CO 2 at temperatures ranging from 35 to 65°C, preferably at 45°C, and pressures ranging from 200 to 260 bar, preferably at 245 bar. In the separator (or in the separators) the temperature ranges from 25 to 45°C and the pressure is of about 50 bar. In these experimental conditions gummy materials, which make the recovery of the desired compounds difficult, are not extracted. The residue can be directly submitted to saponification according to what reported in the examples.
  • Jaeschkenadiol is esterified with jo-pivaloylossibenzoic acid and treated, in the same reaction solvent, with a base, preferably a primary amine, more preferably ethylenediamine, to give pure ferutinine.
  • steps c) and d) are conveniently carried out in sequence without recovery of intermediate ⁇ -pivaloylferutinine.
  • a further object of the present invention is the cosmetic and dermatological use of ferutinine, ⁇ -pivaloylferutinine and extracts, of Ferula spp, preferably Ferula communis and Ferula hermonis extracts.
  • compositions containing ferutinine or Ferula spp extracts can be used in the cosmetic or dermatological field for the treatment of superficial or deep wrinkles or other unaesthetisms, as well as for the treatment of various acne and seborrhea forms.
  • Ferutinine and Ferula spp extracts can be formulated in the form of creams, gels and lotions in admixture with conventional excipients, for example those described in Remington's Pharmaceutical Sciences Handbook, XVII ed., Mack Pub., N.Y., U.S.A., preferably in the presence of soy lecithin or phospholipids, such as lauroylphosphatidylcoline and myristoylphosphatidilcoline, which can be incorporated in water/oil and oil/water emulsions or in transdermal plasters.
  • soy lecithin or phospholipids such as lauroylphosphatidylcoline and myristoylphosphatidilcoline
  • the methanol extract is refluxed with 513 ml of a 10%) KOH methanol solution. After 1 h, TLC analysis (petroleum ether-EtOAc 8/2, ferutinine R f : 0.14; R f jaeschkenadiol: 0.31) shows that the reaction is complete. After cooling, the reaction mixture is diluted with water (500 ml) and extracted with petroleum ether (4 x 500 ml). The combined petroleum ether phases are washed with brine, dried and evaporated. The resulting semicrystalline residue is washed with cold petroleum ether (refrigerator temperature) to obtain 7.5 g of crystalline jaeschkenadiol.
  • the mother liquors are purified by chromatography (50 g silica gel, petroleum-ether-EtOAc 95:5), to obtain ⁇ -bisabolol (870 mg), a mixture of ⁇ -bisabolol and jaeschkenadiol, and pure jaeschkenadiol (3.4 g after crystallization).
  • the mixture of jaeschkenadiol and ⁇ -bisabolol is pooled with the mother liquor and chromatographed (50 g silica gel, petroleum ether-EtOAc 95:5), to obtain 1.95 g of crystalline jaeschkenadiol (overall yield: 12.85 g, 5.1%).
  • the compound has the following chemical-physical and spectroscopic properties: IR spectrum (KBr, cm -1 ): 3339, 2965, 2905, 2875, 1470, 1375, 1047,
  • Example 3 Isolation of jaeschkenadiol from Ferula communis aerial parts 1 kg of finely ground Ferula communis aerial parts are extracted with carbon dioxide at 45 °C and 245 bar in an apparatus for extraction with supercritical gases. In the separator (or in the separators) temperature ranges from 25 to 45 °C and pressure is of about 50 bar. In these conditions gummy materials that make it difficult to recover the desired compounds are not extracted. The residue, which contains only lipophilic compounds and water, is taken up with methanol and treated with bases to hydrolyse jaeschkenadiol esters, as reported in examples 1 and 2. After purification, 5.1 g of pure compound having the same characteristics of the product of example 1 is obtained.
  • Example 4 Synthesis of/J-pivaloyloxybenzoic acid
  • the solution is poured into a separatory funnel and extracted with CH 2 C1 2 (3 x 750 ml).
  • the combined methylene chloride phases are washed with 2 M H 2 SO 4 (4 x 750 ml) and a saturated NaCl solution (1 x 1150 ml), then dried over Na 2 SO (60 g).
  • Example 5 Synthesis of ferutinine from jaeschkenadiol Jaeschkenadiol (100 g, 419.5 mmol) is dissolved under stirring at room temperature in CH 2 C1 2 (600 ml). The resulting solution is added with /?-pivaloyloxybenzoic acid (1.4 equivalents, 587.3 mmol, 130.5 g) and DMAP (0.3 equivalents, 125.9 mmol, 15.4 g). The solution is left under stirring for 10 min. to complete reagents dissolution, then N,N'-dicyclohexylcarbodiimide (DCC, 1.8 equivalents, 755.1 mmol, 155.8 g) is added. The reaction is complete after 2 h.
  • DCC N,N'-dicyclohexylcarbodiimide
  • the solution is concentrated to 2 volumes (200 ml) and diluted with 5 volumes of CH 3 CN (500 ml), thereafter the dicyclohexylurea precipitate is filtered off and washed with 5 more volumes of CH 3 CN (2 x 250 ml).
  • the combined organic phases are poured into a separatory funnel, extracted with 10% w/v Na 2 CO 3 (2 x 250 ml) and with a NaCl saturated solution (1 x 250 ml), then dried over Na 2 SO 4 (100 g).
  • the product-containing fractions are pooled, the solvent is evaporated off under vacuum and the product is dried in a static dryer at 45°C for 24 h.
  • Example 7 Formulation containing ferutinine for the treatment of superficial wrinkles
  • Ferutinine is incorporated into a cream having the following composition:
  • Carbomer 934 (Carbopol 934 P - Goodrich) 0.60 g
  • Polysorbate 60 (Tween 60 - ICI) 5.00 g
  • Carbomer 934 (Carbopol 934 P - Goodrich) 0.60 g
  • Silicone oil 350 cps 0.50 g
  • Polysorbate 60 (Tween 60 - ICI) 5.00 g
  • Example 10 Cosmetic formulation containing Ferula spp extract
  • Ferula hermonis extract 0.5 g
  • the effectiveness of the cream of example 7 was determined in a double blind study with 40 female volunteers, of age ranging from 39 to 56, evaluating the effects on skin elasticity and firmness and on rugometry. The study was preceded by a seven days conditioning period, wherein the subject had to refrain from the use of moisturizing products, sun-creams and liquid make-ups and to avoid tanning treatments and excessive exposition to UV rays.
  • the subjects were allowed to use conventional eye and lip care products, face powders and non moisturizing soaps.
  • the subjects were randomly divided into two groups, one treated with a placebo cream and one treated with the cream of example 7.
  • the creams were applied on the face in standardized amount (0.5 g, i.e. 0.5 cm of cream coming out of the tube) twice a day, morning and night. Before and after five weeks of treatment the following measurements were carried out.
  • Each session comprised three measurements with corneometer, three measurements with cutometer, and a silicon impression of the periorbital area, on the skin areas indicated in the following.
  • Cutometry Cutometer is a commercially available device (Cutometer SEM 575,
  • the test was carried out using the cutometer on both cheeks.
  • Corneometer is a commercially available device (Corneometer CM 825 Combi 3, Courage & Khazaka, Germany) which measures capacitance changes resulting from changes in skin hydration. The test was carried out using the corneometer on both cheeks.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/EP2004/003055 2003-04-04 2004-03-23 A process for the preparation of ferutinine from ferula genus plants Ceased WO2004087179A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
KR1020117014703A KR101169893B1 (ko) 2003-04-04 2004-03-23 페루라 속 식물에서 페루티닌의 제조 방법
AT04722572T ATE517631T1 (de) 2003-04-04 2004-03-23 Prozess zur herstellung von ferutinin aus pflanzen der ferulafamilie
PL04722572T PL1615651T3 (pl) 2003-04-04 2004-03-23 Sposób otrzymywania ferutyniny z roślin z rodzaju Ferula
EP04722572A EP1615651B1 (en) 2003-04-04 2004-03-23 A process for the preparation of ferutinine from ferula genus plants
JP2006504815A JP4648305B2 (ja) 2003-04-04 2004-03-23 フェルラ属植物からフェルチニンを製造する方法
AU2004226853A AU2004226853B2 (en) 2003-04-04 2004-03-23 A process for the preparation of ferutinine from Ferula genus plants
BRPI0409166-3A BRPI0409166B1 (pt) 2003-04-04 2004-03-23 Processo para preparação de ferutinina a partir de plantas do gênero ferula e uso de p-pivaloilóxi-ferutina
CA2521100A CA2521100C (en) 2003-04-04 2004-03-23 A process for the preparation of ferutinine from ferula genus plants
DK04722572.7T DK1615651T3 (da) 2003-04-04 2004-03-23 Fremgangsmåde til fremstilling af ferutinin fra Ferula plantefamilier
SI200431757T SI1615651T1 (sl) 2003-04-04 2004-03-23 Proces za pripravo ferutinina iz rastlin rodu ferula
HK06107824.1A HK1087618B (en) 2003-04-04 2004-03-23 A process for the preparation of ferutinine from ferula genus plants
KR1020057018336A KR101132526B1 (ko) 2003-04-04 2004-03-23 페루라 속 식물에서 페루티닌의 제조 방법
US10/551,772 US7371886B2 (en) 2003-04-04 2004-03-23 Process for the preparation of ferutinine from Ferula genus plants
IL171230A IL171230A (en) 2003-04-04 2005-10-02 A process for making protein from plants of the ferula type
NO20054545A NO333671B1 (no) 2003-04-04 2005-10-03 Fremgangsmate for fremstilling av ferutinin fra Ferula genusplanter og kosmetisk behandling av rynker.
US12/058,776 US20080248139A1 (en) 2003-04-04 2008-03-31 Process for the preparation of ferutinine from ferula genus plants
US12/816,671 US8101215B2 (en) 2003-04-04 2010-06-16 Process for cosmetic treatment using ferutinine from Ferula genus plants
US13/324,339 US8247005B2 (en) 2003-04-04 2011-12-13 Process for cosmetic treatment using ferutinine from Ferula genus plants

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000661A ITMI20030661A1 (it) 2003-04-04 2003-04-04 Processo per la preparazione della ferutinina da piante del genere ferula
ITMI2003A000661 2003-04-04

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10551772 A-371-Of-International 2004-03-23
US12/058,776 Division US20080248139A1 (en) 2003-04-04 2008-03-31 Process for the preparation of ferutinine from ferula genus plants

Publications (1)

Publication Number Publication Date
WO2004087179A1 true WO2004087179A1 (en) 2004-10-14

Family

ID=33105046

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/003055 Ceased WO2004087179A1 (en) 2003-04-04 2004-03-23 A process for the preparation of ferutinine from ferula genus plants

Country Status (19)

Country Link
US (4) US7371886B2 (enExample)
EP (1) EP1615651B1 (enExample)
JP (2) JP4648305B2 (enExample)
KR (2) KR101169893B1 (enExample)
CN (2) CN101371818A (enExample)
AT (1) ATE517631T1 (enExample)
AU (1) AU2004226853B2 (enExample)
BR (1) BRPI0409166B1 (enExample)
CA (2) CA2521100C (enExample)
DK (1) DK1615651T3 (enExample)
ES (1) ES2367361T3 (enExample)
IL (1) IL171230A (enExample)
IT (1) ITMI20030661A1 (enExample)
NO (1) NO333671B1 (enExample)
PL (1) PL1615651T3 (enExample)
PT (1) PT1615651E (enExample)
RU (2) RU2342153C2 (enExample)
SI (1) SI1615651T1 (enExample)
WO (1) WO2004087179A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012152940A3 (en) * 2011-05-12 2013-01-03 B.R.A.I.N. Biotechnology Research And Information Network Ag Small molecule inhibitors of trpa1
US9913799B2 (en) 2014-07-11 2018-03-13 Mary Kay Inc. Cosmetic compositions and methods of their use
WO2019150266A1 (en) * 2018-01-30 2019-08-08 Alaryani Humaid Saeed Mohammad Sultan Preparation for treatment of wounds

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20032286A1 (it) * 2003-11-24 2005-05-25 Indena Spa Composizioni per il trattamento di dermatiti atopiche di stati allergici cutanei e dell'acne
US8536584B2 (en) 2007-11-14 2013-09-17 Cree, Inc. High voltage wire bond free LEDS
US20100260695A1 (en) * 2009-04-09 2010-10-14 Mary Kay Inc. Combination of plant extracts to improve skin tone
CA2800383C (en) * 2010-05-24 2019-06-25 Indena S.P.A. Tamarind seed polysaccharide for use in the treatment of inflammatory diseases
CN105820146A (zh) * 2015-01-08 2016-08-03 辽宁医联新药研究所 一种阿魏内酯及其提取纯化的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1604225A (en) * 1978-05-15 1981-12-02 Skourides A A Extract of ambelferae for pharmacological use
CH672251A5 (enExample) * 1987-05-29 1989-11-15 Inst Khim Rastitelnykh Vesches
JP2001206819A (ja) * 2000-01-24 2001-07-31 Sansho Seiyaku Co Ltd 美白化粧料

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2090198C1 (ru) * 1991-03-12 1997-09-20 Иван Иванович Уваров Способ получения биологически активных веществ, обладающих противогрибковой активностью
DE4444238A1 (de) * 1994-12-13 1996-06-20 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden
CA2417552C (en) * 2000-06-27 2014-05-13 Qualilife Pharmaceuticals Inc. Compositions and methods for treating females sexual response
US6623768B1 (en) * 2002-04-16 2003-09-23 Yousry M. A. Naguib Pharmaceutically active composition extracted from Ferula hermonis and process of its extraction

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1604225A (en) * 1978-05-15 1981-12-02 Skourides A A Extract of ambelferae for pharmacological use
CH672251A5 (enExample) * 1987-05-29 1989-11-15 Inst Khim Rastitelnykh Vesches
JP2001206819A (ja) * 2000-01-24 2001-07-31 Sansho Seiyaku Co Ltd 美白化粧料

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GALAL A M ET AL: "Daucane sesquiterpenes from Ferula hermonis.", JOURNAL OF NATURAL PRODUCTS. MAR 2001, vol. 64, no. 3, March 2001 (2001-03-01), pages 399 - 400, XP002290428, ISSN: 0163-3864 *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 24 11 May 2001 (2001-05-11) *
TAMEMOTO KIMIKO ET AL: "Sesquiterpenoids from the fruits of Ferula kuhistanica and antibacterial activity of the constituents of F. kuhistanica", PHYTOCHEMISTRY (OXFORD), vol. 58, no. 5, November 2001 (2001-11-01), pages 763 - 767, XP004310053, ISSN: 0031-9422 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012152940A3 (en) * 2011-05-12 2013-01-03 B.R.A.I.N. Biotechnology Research And Information Network Ag Small molecule inhibitors of trpa1
US9440993B2 (en) 2011-05-12 2016-09-13 B.R.A.I.N. Biotechnology Research And Information Network Ag Small molecule inhibitors of TRPA1
US10000438B2 (en) 2011-05-12 2018-06-19 B.R.A.I.N. Biotechnology Research And Information Network Ag Small molecule inhibitors of TRPA1
US9913799B2 (en) 2014-07-11 2018-03-13 Mary Kay Inc. Cosmetic compositions and methods of their use
US10123968B2 (en) 2014-07-11 2018-11-13 Mary Kay Inc. Cosmetic compositions and methods of their use
US10231922B2 (en) 2014-07-11 2019-03-19 Mary Kay Inc. Cosmetic compositions and methods of their use
US10617633B2 (en) 2014-07-11 2020-04-14 Mary Kay Inc. Cosmetic compositions and methods of their use
US11969498B2 (en) 2014-07-11 2024-04-30 Mary Kay Inc. Cosmetic compositions and methods of their use
WO2019150266A1 (en) * 2018-01-30 2019-08-08 Alaryani Humaid Saeed Mohammad Sultan Preparation for treatment of wounds

Also Published As

Publication number Publication date
KR20060008307A (ko) 2006-01-26
NO333671B1 (no) 2013-08-05
EP1615651A1 (en) 2006-01-18
HK1087618A1 (zh) 2006-10-20
CA2766702C (en) 2015-09-29
US8101215B2 (en) 2012-01-24
CN100518732C (zh) 2009-07-29
ITMI20030661A1 (it) 2004-10-05
US8247005B2 (en) 2012-08-21
US20100255125A1 (en) 2010-10-07
RU2008122295A (ru) 2009-12-10
EP1615651B1 (en) 2011-07-27
NO20054545D0 (no) 2005-10-03
JP5409505B2 (ja) 2014-02-05
CN1767841A (zh) 2006-05-03
PL1615651T3 (pl) 2011-12-30
IL171230A (en) 2014-02-27
US20120095094A1 (en) 2012-04-19
NO20054545L (no) 2005-10-06
AU2004226853A1 (en) 2004-10-14
JP2010209099A (ja) 2010-09-24
CA2521100C (en) 2012-05-01
RU2342153C2 (ru) 2008-12-27
KR101132526B1 (ko) 2012-04-03
US20080248139A1 (en) 2008-10-09
ATE517631T1 (de) 2011-08-15
KR101169893B1 (ko) 2012-07-31
KR20110082091A (ko) 2011-07-15
DK1615651T3 (da) 2011-10-24
RU2005130639A (ru) 2006-04-27
RU2469733C2 (ru) 2012-12-20
CA2766702A1 (en) 2004-10-14
US7371886B2 (en) 2008-05-13
BRPI0409166B1 (pt) 2015-09-01
JP4648305B2 (ja) 2011-03-09
CA2521100A1 (en) 2004-10-14
SI1615651T1 (sl) 2011-11-30
BRPI0409166A (pt) 2006-04-11
PT1615651E (pt) 2011-09-02
JP2006522043A (ja) 2006-09-28
US20060275246A1 (en) 2006-12-07
ES2367361T3 (es) 2011-11-02
AU2004226853B2 (en) 2009-06-04
CN101371818A (zh) 2009-02-25

Similar Documents

Publication Publication Date Title
US8247005B2 (en) Process for cosmetic treatment using ferutinine from Ferula genus plants
AU2012208626B2 (en) Monoterpene derivatives of chalcone or dihydrochalcone and their use as depigmenting agents
FR3026011B1 (fr) Composition contenant au moins un inhibiteur de certaines chimiokines, son procede d'obtention et son utilisation dermocosmetique pharmaceutique
JP2006522043A5 (enExample)
JP2002534406A (ja) 皮膚美白用組成物
KR101048477B1 (ko) 인돌알칼로이드계 화합물을 함유하는 피부 미백용 조성물
KR100570810B1 (ko) 신규 세라마이드 유도체, 이의 제조방법 및 이의 용도
HK1087618B (en) A process for the preparation of ferutinine from ferula genus plants
HK1126391A (en) A process for the preparation of ferutinine from ferula genus plants
JP2003306421A (ja) メラノサイトのデンドライト伸長抑制剤及びそれを含有してなる皮膚外用剤
KR101784759B1 (ko) 이리게닌을 유효성분으로 함유하는 피부미백용 화장료 조성물
KR101558526B1 (ko) 붉은싸리버섯 추출물을 유효성분으로 함유하는 항노화용 조성물
JP2007161684A (ja) トリテルペン化合物およびそれを有効成分として含む皮膚外用剤
JP2004315491A (ja) 皮膚外用剤
JP2005023242A (ja) 抗酸化剤及び皮膚外用剤
JP2004182709A (ja) 皮膚外用剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1020057018336

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004226853

Country of ref document: AU

Ref document number: 20048091113

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 171230

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006275246

Country of ref document: US

Ref document number: 2521100

Country of ref document: CA

Ref document number: 4469/DELNP/2005

Country of ref document: IN

Ref document number: 10551772

Country of ref document: US

Ref document number: 2005130639

Country of ref document: RU

Ref document number: 2006504815

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004722572

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004226853

Country of ref document: AU

Date of ref document: 20040323

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004226853

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004722572

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057018336

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0409166

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10551772

Country of ref document: US